OBJECTIVE: Myeloperoxidase (MPO) locally contributes to organ damage in various chronic inflammatory conditions by generating reactive intermediates. The contribution of MPO in the development of experimental lupus is unknown. The aim of this study was to define the role of MPO in murine lupus nephritis (LN). METHODS: LN was induced in C57BL/6 wild-type (WT) and MPO knockout (MPO(-/-) ) mice by intraperitoneal injection of pristane. Autoimmunity and glomerulonephritis were assessed 20 and 40 weeks after pristane administration. Cell apoptosis, leukocyte accumulation, and cytokine levels in the peritoneal cavity of WT and MPO(-/-) mice were assessed 3 or 6 days after pristane injection. RESULTS: MPO(-/-) mice developed more severe nephritis than did WT mice 20 and 40 weeks after pristane injection, despite having reduced glomerular deposition of antibody and complement and diminished levels of markers of oxidative stress (oxidized DNA and glutathione sulfonamide). Enhancement of renal disease in MPO-deficient mice correlated with increased accumulation of CD4+ T cells and macrophages in glomeruli, which, in turn, was associated with augmented generation of CD4+ T cell responses and increased activation and migration of dendritic cells in secondary lymphoid organs. In addition, the enhanced renal injury in MPO(-/-) mice was associated with increased glomerular accumulation of neutrophils and deposition of neutrophil extracellular traps. MPO deficiency also increased early cell apoptosis, leukocyte accumulation, and proinflammatory cytokine expression in the peritoneum. CONCLUSION: MPO attenuates pristane-induced LN by inhibiting early inflammatory responses in the peritoneum and limiting the generation of CD4+ T cell autoimmunity in secondary lymphoid organs.
OBJECTIVE:Myeloperoxidase (MPO) locally contributes to organ damage in various chronic inflammatory conditions by generating reactive intermediates. The contribution of MPO in the development of experimental lupus is unknown. The aim of this study was to define the role of MPO in murinelupus nephritis (LN). METHODS: LN was induced in C57BL/6 wild-type (WT) and MPO knockout (MPO(-/-) ) mice by intraperitoneal injection of pristane. Autoimmunity and glomerulonephritis were assessed 20 and 40 weeks after pristane administration. Cell apoptosis, leukocyte accumulation, and cytokine levels in the peritoneal cavity of WT and MPO(-/-) mice were assessed 3 or 6 days after pristane injection. RESULTS:MPO(-/-) mice developed more severe nephritis than did WT mice 20 and 40 weeks after pristane injection, despite having reduced glomerular deposition of antibody and complement and diminished levels of markers of oxidative stress (oxidized DNA and glutathione sulfonamide). Enhancement of renal disease in MPO-deficientmice correlated with increased accumulation of CD4+ T cells and macrophages in glomeruli, which, in turn, was associated with augmented generation of CD4+ T cell responses and increased activation and migration of dendritic cells in secondary lymphoid organs. In addition, the enhanced renal injury in MPO(-/-) mice was associated with increased glomerular accumulation of neutrophils and deposition of neutrophil extracellular traps. MPO deficiency also increased early cell apoptosis, leukocyte accumulation, and proinflammatory cytokine expression in the peritoneum. CONCLUSION:MPO attenuates pristane-induced LN by inhibiting early inflammatory responses in the peritoneum and limiting the generation of CD4+ T cell autoimmunity in secondary lymphoid organs.
Authors: Roman Mehling; Johannes Schwenck; Christina Lemberg; Christoph Trautwein; Laimdota Zizmare; Daniela Kramer; Anne Müller; Birgit Fehrenbacher; Irene Gonzalez-Menendez; Leticia Quintanilla-Martinez; Katrin Schröder; Ralph P Brandes; Martin Schaller; Wolfram Ruf; Martin Eichner; Kamran Ghoreschi; Martin Röcken; Bernd J Pichler; Manfred Kneilling Journal: Theranostics Date: 2021-01-01 Impact factor: 11.556
Authors: Faith M Strickland; Dipak Patel; Dinesh Khanna; Emily Somers; Aaron M Robida; Michael Pihalja; Richard Swartz; Wendy Marder; Bruce Richardson Journal: Lupus Sci Med Date: 2016-04-04
Authors: Silvie Kremserova; Tomas Perecko; Karel Soucek; Anna Klinke; Stephan Baldus; Jason P Eiserich; Lukas Kubala Journal: Oxid Med Cell Longev Date: 2016-02-21 Impact factor: 6.543
Authors: Federica Agliano; Keaton S Karlinsey; Michael Ragazzi; Antoine Ménoret; Anthony T Vella Journal: Sci Rep Date: 2020-07-21 Impact factor: 4.379
Authors: Rachael A Gordon; Jeremy S Tilstra; Anthony Marinov; Kevin M Nickerson; Sheldon I Bastacky; Mark J Shlomchik Journal: PLoS One Date: 2020-04-03 Impact factor: 3.240